Intercept Pharmaceuticals (Nasdaq: ICPT) stock surged 45% today (Tuesday) to a new 52-week high of $349.08 after the company reported Q2 results and provided promising updates on several of its key drugs.
Updated August 14, 2014: Pfizer stock (NYSE: PFE) will soon feel the pressure from the wave of lawsuits being filed claiming that Pfizer's blockbuster drug Lipitor - the world's best-selling drug of all time - causes type-2 diabetes in women.
"This will be a huge overhang on Pfizer stock," Money Morning Capital Wave Strategist Shah Gilani said. "Investors have to watch developments closely."
With a market cap of more than $180 billion, the world's largest pharmaceutical firm's pockets run deep. Lipitor alone brought in global sales of more than $125 billion for Pfizer over the 14-and-a-half years since its 1996 market debut (Pfizer's patent on Lipitor expired on November 30, 2011). More than 29 million patients took the drug just in the United States.
Gilead Sciences Inc. (Nasdaq: GILD) stock hit a 52-week high of $92.97 this morning (Thursday) after the company crushed earnings estimates last night. At that price, the stock was up 3% from yesterday's closing price.
Money Morning’s Defense and Tech Specialist Michael Robinson has been high on GILD stock for some time, and yesterday’s huge earnings beat comes as no surprise to Money Morning readers. Here’s why this hot biotech stock is just getting started.
This is not a misprint: Puma Biotechnology Inc. (NYSE: PBYI) stock surged nearly 300%, or $176.63, to an all-time high of $234.99 intraday Wednesday.
Founded in 2010 and based in Los Angeles, Puma doesn't have a single drug yet on the market.
Stock market today, July 16, 2014: U.S. stock markets slacked on Tuesday after statements by U.S. Federal Reserve Chair Janet Yellen in front of the Senate Banking Committee indicated that some sectors might be overvalued. Biotech and social media shares slumped in the afternoon. The iShares Nasdaq Biotechnology Index ETF (Nasdaq: IBB) slumped by more than 2.5% after Yellen's testimony.
Stock Market Today, July 15, 2014: U.S. markets slacked on Tuesday after statements by U.S. Federal Reserve Chair Janet Yellen in front of the Senate Banking Committee indicated that some sectors might be overvalued. Biotech and social media shares slumped in the afternoon. The iShares Nasdaq Biotechnology Index ETF (Nasdaq: IBB) slumped by more than 2.5% after Yellen's testimony.
Last week, we covered a "catalyst" that could spark a share-price rally for what is already one of the best stocks to buy, three recommendations to take advantage of rising oil prices, and a way to tap into big profits in an "other" bioscience niche that is less risky but highly lucrative.
With just six months left on my 2014 bioscience "profit calendar," things are really starting to look promising for the second half of 2014. There are huge opportunities in several subsectors of the bioscience market in particular.
That said, some bioscience analysts are saying there's a bubble. And it's scaring a lot of bioscience investors out of great positions in the market.
That's why last week I shared my complete bioscience market outlook for the rest of 2014 with my paid members - to help them see the real market story.
Today I want to share with you some of my thinking, expectations, and predictions, as well as my strategy to get us tapped in to a segment of the bioscience market we haven't even touched yet.
This segment has been tremendously profitable for some of the world's biggest drug companies, and I think there are going to be some killer profits for us there, too... Full Story
IPO Calendar 2014 update: This year, 212 companies have already held IPOs, and the healthcare industry has seen more companies go public than any sector.
Through Monday, 51 healthcare companies have made initial public offerings, accounting for 24% of the total U.S. IPO market.
Healthcare stocks are once again at the forefront of the IPO calendar this week as five of this week's seven IPOs are healthcare companies.
At first glance, it may seem like bioscience investing is so complicated and risky that it's hardly worth your time and money to invest, at least if you don't have someone knowledgeable to guide you.
And it's true. Putting your money behind new, experimental drugs, without some guidance, is a crapshoot.
But there's an approach to making profits from this sector that doesn't rely on breakthrough discoveries, expensive drug trials, or constant cash infusions through dilutive public offerings to fuel its engine.
That's what makes the company we'll look at today such an attractive investment.
Welcome to the lucrative world of generics...
Vertex Pharmaceuticals Inc. (Nasdaq: VRTX) tops Tuesday's hot stocks to watch list. Shares skyrocketed 50% intraday after the biotech company deemed its cystic fibrosis treatment a success.
Also landing on today's hot stocks list are a number of penny stocks, a semiconductor company, and several stocks moving up on analysts' action and M&A activity.
Late last month, I told you that biotech is one of the best ways to profit from the tech rebound.
Somewhat ironically, a rollover in biotech stocks was one of the proximate causes of the overall sell-off in tech earlier this year.
And now I'm recommending that you invest in the company that purportedly "caused" the biotech market to roll over in the first place.
Each week our Money Morning experts dish out the latest profit plays - and asset-protection moves - for our Money Morning Members - all for free.
Last week, Money Morning's best stocks to buy included five biotech picks. Four of them are blazing trails in immuno-oncology. Our fifth biotech pick has already tripled in value in the last six months, and it's not done yet.
Aside from these biotech winners, we covered an ETF play on the European Central Bank's recent policy changes, the best stock in "unified computing," and a smart gold buy at a discount.
Usually the best stocks to buy have not already tripled in value within the past six months.
But then there's Intercept Pharmaceuticals Inc. (Nasdaq: ICPT).
This biotech stock soared more than 500% in two days on the news its innovative and promising hepatitis drug obeticholic acid, or OCA, had a trial stopped early because the drug met the goals of the study.
Bulls have refused to be distracted by some negative news that has pushed the stock back under $300 in the meantime.
In bioscience investing, binary catalysts are milestone events that signal a thumbs-up or thumbs- down for an experimental drug as it makes its way through the regulatory process.
Positive catalysts can send a share price soaring. Negative ones can send it into a nosedive.
Perhaps the least understood of these catalysts are FDA Advisory Committee (a.k.a. AdCom) recommendations.
But they're also among the most powerful.
Here's what I mean, and how to play them profitably... Full Story